Neurocrine Biosciences (NBIX) EBITDA Margin Growth (1y) (2011 - 2026)
Neurocrine Biosciences (NBIX) EBITDA Margin Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 304.00 |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -157.00 |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -5,330.00 |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -650.00 |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 8,630.00 |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1,962.00 |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 111.00 |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 31.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,962.00 |
| Dec 31, 2025 | 356.00 |
| Sep 30, 2025 | 52.00 |
| Jun 30, 2025 | -346.00 |
| Mar 31, 2025 | -1,515.00 |
| Dec 31, 2024 | -655.00 |
| Sep 30, 2024 | 124.00 |
| Jun 30, 2024 | 838.00 |
| Mar 31, 2024 | 4,643.00 |
| Dec 31, 2023 | 408.00 |
| Sep 30, 2023 | 567.00 |
| Jun 30, 2023 | -25,724.00 |
| Mar 31, 2023 | -2,816.00 |
| Dec 31, 2022 | 3,673.00 |
| Sep 30, 2022 | 760.00 |
| Jun 30, 2022 | 25,176.00 |
| Mar 31, 2022 | -1,232.00 |
| Dec 31, 2021 | -4,060.00 |
| Sep 30, 2021 | 3,217.00 |
| Jun 30, 2021 | -359.00 |